Shots:

• Sanofi acquires Bioverativ- in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value as $11.6B
• The focus of the agreement is to combine Bioverativ’s expertise with its platform for the advancement of fitusiran to treat Hemophilia A and B and further strengthening Sanofi’s footprints in rare diseases
• Fitusiran is a once-monthly RNA interference (RNAi) therapeutic- targeted for hemophilia A and B with and without inhibitors

Ref: Eli Lilly | Image: The Street